Pharm
5-HT3 Receptor Antagonist
search
5-HT3 Receptor Antagonist
, 5-HT3 Antagonist, Serotonin 5-HT3 Receptor Antagonist
See Also
Ondansetron
Dolasetron
Palonosetron
Granisetron
Nausea in Cancer
Indications
Chemotherapy
associated
Nausea
Radiation Therapy
associated
Nausea
Vomiting
refractory to first-line
Antiemetic
s
Theophylline
Overdose
Used instead of
Phenothiazine
s due to
Seizure
risk
Mechanism
Blocks peripheral and central 5HT3 receptors
Peripheral 5HT3 receptors at vagal nerve terminals
Central 5HT3 receptors at
Chemoreceptor
Trigger Zone
in
Medulla
(area postrema controls
Vomiting
)
Contraindications
QTc Prolongation
First trimester pregnancy (
Ondansetron
)
See
Ondansetron
Ondansetron
has a relative contraindication based on preliminary data
However it is also frequently used in
Hyperemesis Gravidarum
Adverse Effects
Mild
Headache
Dizziness
Malaise or
Fatigue
Constipation
QTc Prolongation
(
Ondansetron
,
Dolasetron
)
See
Ondansetron
Higher risk in higher doses, preexisting
QTc Prolongation
, CHF,
Bradycardia
,
Hypomagnesemia
,
Hypokalemia
Serotonin Syndrome
http://www.fda.gov/Drugs/GuidanceComplianceRegulatoryInformation/Surveillance/AdverseDrugEffects/ucm351864.htm
Dosing
Ondansetron
(
Zofran
)
See
Ondansetron
Adults
Take 4 mg ODT tabs (typical acute care dosing)
Children
Exercise
caution in age <6 months
Weight 8-15 kg:
Ondansetron
2 mg (half tab)
Weight 15-30 kg:
Ondansetron
4 mg (one tab)
Weight >30 kg:
Ondansetron
4 to 8 mg (one to two tabs)
Freedman (2006) N Engl J Med 354:1698-705 [PubMed]
Dosing
Dolasetron
(
Anzemet
)
See
Dolasetron
Gene
ral
Pregnancy Category B
Nausea
with
Chemotherapy
Adult 100 mg IV or orally given 60 minutes before
Chemotherapy
Child: 1.8 mg/kg for single dose up to 100 mg IV or orally given 60 minutes before
Chemotherapy
Prevention of Surgery Related
Nausea
Adult: 100 mg orally 2 hours before surgery
Child: 1.2 mg/kg up to 100 mg orally 2 hours before surgery
Surgery Related
Nausea
or
Vomiting
Given perioperatively for
Nausea
or
Vomiting
, or prophylactically 15 min before
Anesthesia
ends
Adult: 12.5 mg IV for single dose
Child: 0.35 mg/kg up to 12.5 mg IV for single dose
Resources
Dolasetron
(DailyMed)
https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=201b0eb8-4a1e-4e22-ab4b-addb642710d6
Dosing
Granisetron
(
Kytril
,
Sustol
,
Sancuso
)
See
Granisetron
Gene
ral
Pregnancy Category B
Nausea
with
Chemotherapy
Intravenous: 10 mcg/kg IV over 5 minutes given 30 minutes before
Chemotherapy
SQ (
Sustol
): 10 mg SQ given 30 min prior to
Chemotherapy
Oral: 2 mg orally once daily OR 1 mg orally twice daily given 1 hour before
Chemotherapy
Transdermal (
Sancuso
, 34 mg patch delivers 3.1 mg per 24 hours)
Apply 1 patch to upper outer arm 24 to 48 hours before
Chemotherapy
Remove 24 hours after
Chemotherapy
(may use 1 patch continuously for up to 7 days)
Avoid exposing patch to heat or sunlight
Nausea
with
Radiation Therapy
(adult)
Dose: 2 mg orally 1 hour before each
Radiation Therapy
treatment
Resources
Granisetron
(DailyMed)
https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=02f350c9-b7d2-4906-af28-70ed4461ff23
Dosing
Palonosetron
(
Aloxi
)
See
Palonosetron
Gene
ral
Palonosetron
is also available combined with the NK1
Antagon
ist
Netupitant
(
Akynzeo
)
Pregnancy Category B
Indications: Preventing
Chemotherapy
indiuced
Nausea
Not effective in treating
Nausea
after it occurs
Most effective in preventing delayed
Emesis
Longer
Half-Life
(>40 hours) and higher
5-HT
affinity than other 5HT3
Antagonist
s
Precautions
Do NOT repeat dose more than once weekly
Nausea
with
Chemotherapy
Adult: 0.25 mg IV over 30 seconds, given 30 min before
Chemotherapy
Child: 20 mcg/kg up to 1.5 mg IV over 15 min, given 30 min before
Chemotherapy
Prevention of Surgery Related
Nausea
Give 0.075 mg IV over 10 seconds, before
Anesthesia
Resources
Palonosetron
(DailyMed)
https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=bb20ba9b-aa8c-4b24-8124-aff0cb6c956b
References
(2004) Med Lett Drugs Ther 46(1179): 27-8 [PubMed]
References
Johnson (1993) Harriet Lane, Mosby, p. 521
(2002) Tarascon Pocket Pharmacopoeia, p. 67
(1998) Med Lett Drugs Ther 40(1026): 53-4 [PubMed]
(1991) Med Lett Drugs Ther 33(847): 63-4 [PubMed]
Bell and Lovecchio (2016) Crit Dec Emerg Med 30(8): 28
Type your search phrase here